ATE284224T1 - Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung - Google Patents

Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung

Info

Publication number
ATE284224T1
ATE284224T1 AT00976116T AT00976116T ATE284224T1 AT E284224 T1 ATE284224 T1 AT E284224T1 AT 00976116 T AT00976116 T AT 00976116T AT 00976116 T AT00976116 T AT 00976116T AT E284224 T1 ATE284224 T1 AT E284224T1
Authority
AT
Austria
Prior art keywords
heterotrimeric
signal transduction
anticancer agent
therapeutic use
inhibitor
Prior art date
Application number
AT00976116T
Other languages
English (en)
Inventor
Gregoire Prevost
Marie-Odile Lonchampt
Thomas Gordon
Barry Morgan
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9914037A external-priority patent/FR2800616B1/fr
Priority claimed from FR0000104A external-priority patent/FR2803524B1/fr
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of ATE284224T1 publication Critical patent/ATE284224T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00976116T 1999-11-09 2000-11-08 Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung ATE284224T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9914037A FR2800616B1 (fr) 1999-11-09 1999-11-09 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR0000104A FR2803524B1 (fr) 2000-01-06 2000-01-06 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
PCT/FR2000/003098 WO2001034203A1 (fr) 1999-11-09 2000-11-08 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer

Publications (1)

Publication Number Publication Date
ATE284224T1 true ATE284224T1 (de) 2004-12-15

Family

ID=26212071

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00976116T ATE284224T1 (de) 1999-11-09 2000-11-08 Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung

Country Status (15)

Country Link
US (3) US7034024B1 (de)
EP (2) EP1430934A1 (de)
JP (1) JP2003513940A (de)
AT (1) ATE284224T1 (de)
AU (1) AU1400401A (de)
CA (1) CA2390317C (de)
CZ (1) CZ20021550A3 (de)
DE (1) DE60016625T2 (de)
DK (1) DK1233787T3 (de)
ES (1) ES2234692T3 (de)
HU (1) HUP0203241A3 (de)
PL (1) PL204716B1 (de)
PT (1) PT1233787E (de)
RU (1) RU2298417C2 (de)
WO (1) WO2001034203A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
KR100594353B1 (ko) * 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
DE102009033392A1 (de) * 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
EP3590940B1 (de) * 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrol-derivate und verwandte verbindungen als autotaxin (atx) inhibitoren und als inhibitoren der lysophosphatinsäure (lpa) produktion zur behandlung von z.b. nierenerkrankungen
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN106317057B (zh) * 2015-07-02 2019-02-01 北京桦冠医药科技有限公司 具有咪唑并吡嗪类衍生物，其制备及其在医药上的应用
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
AU2018260414A1 (en) 2017-04-24 2019-10-17 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0517353A (ja) * 1991-07-10 1993-01-26 Kanebo Ltd 制癌作用増強剤
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
BR9814419A (pt) * 1997-12-22 2000-10-10 Schering Corp "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase

Also Published As

Publication number Publication date
HUP0203241A2 (hu) 2003-02-28
DE60016625D1 (de) 2005-01-13
PL356028A1 (en) 2004-06-14
HUP0203241A3 (en) 2006-07-28
DK1233787T3 (da) 2005-08-15
DE60016625T2 (de) 2005-12-22
WO2001034203A1 (fr) 2001-05-17
US20060074078A1 (en) 2006-04-06
CA2390317A1 (fr) 2001-05-17
PT1233787E (pt) 2005-04-29
EP1430934A1 (de) 2004-06-23
ES2234692T3 (es) 2005-07-01
RU2002115262A (ru) 2004-01-27
JP2003513940A (ja) 2003-04-15
PL204716B1 (pl) 2010-02-26
EP1233787B8 (de) 2005-05-18
RU2298417C2 (ru) 2007-05-10
CA2390317C (fr) 2010-03-23
AU1400401A (en) 2001-06-06
EP1233787B1 (de) 2004-12-08
EP1233787A1 (de) 2002-08-28
US7034024B1 (en) 2006-04-25
US20090270341A1 (en) 2009-10-29
CZ20021550A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
DE60016625D1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
NO903944L (no) Fremgangsmaate for fremstilling av nye peptidase og isomerase-inhibitorer.
SE9800836D0 (sv) New Compounds
ATE375794T1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
NO20031521D0 (no) Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme
CY1110426T1 (el) Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιων
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
WO2003080582A3 (de) Fredericamycin-derivate
ME00578A (en) Use of gastrointestinal lipase inhibitors
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
DK1905457T3 (da) Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
HUP0302136A2 (hu) Endogén véralvadást aktíváló vegyületek és alkalmazásuk az endogén véralvadás feltárásában
WO2001000184A3 (de) Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln
GB9811221D0 (en) Bacterial-pheromones and uses therefor
DE60112719D1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterometrischen g proteinen in kombination mit einem antihypertensiven mittel zu einer therapeutischen verwendung in der behandlung von arterieller hypertonie
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DK1503803T3 (da) Injicerbar farmaceutisk sammensætning indeholdende ethanol til at behandle diskusprolaps
WO2003077841A3 (en) Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
WO2001070953A3 (en) Identification of modulators of the inteferon gamma signaling pathway and their use in restenosis treatment
WO2001000189A3 (de) Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln
WO2003047571A3 (de) Verwendung eines kmo-inhibitors zur herstellung einer pharmazeutischen zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1233787

Country of ref document: EP

EEIH Change in the person of patent owner